Enliven Therapeutics (ELVN) to Release Earnings on Tuesday

Enliven Therapeutics (NASDAQ:ELVN) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.51) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $18.51 on Monday. The company has a market cap of $908.21 million, a PE ratio of -9.74 and a beta of 1.07. The business has a 50-day simple moving average of $19.06 and a two-hundred day simple moving average of $21.99. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Insider Buying and Selling

In related news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $18.39, for a total transaction of $122,606.13. Following the completion of the sale, the chief operating officer now owns 309,976 shares of the company’s stock, valued at $5,700,458.64. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $20.08, for a total value of $107,026.40. Following the sale, the chief executive officer now directly owns 980,062 shares of the company’s stock, valued at $19,679,644.96. This trade represents a 0.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 76,111 shares of company stock valued at $1,493,145 over the last quarter. 29.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.